The Asia Pacific Actinic Keratosis Treatment Market should witness market growth of 5.2% CAGR during the forecast period (2022-2028).
There are numerous actinic keratosis treatment methods nowadays. The most commonly employed methods include cryotherapy, excision, chemical peels, and photodynamic therapy. A chemical peel resembles a high-end face mask. During an office visit, the healthcare professional apply the peel. The treatment's ingredients safely remove any unwelcome skin growths from the epidermis. The treated region remains painful and red for the first few days.
Before beginning the excision procedure, the doctor numbs the area around the AK. The AKs are then removed surgically or by scraping, and the wound is stitched back up. The wound typically heals in two to three weeks. Photodynamic therapy may be suggested by the doctor if patients have several AKs or AKs that recur after treatment. In order to eliminate precancerous skin cells, this treatment employs lotions and specialized light therapy. While the treated skin heals, the patient will need to avoid the sun for a few days.
Additionally, the coronavirus disease pandemic of 2019 (COVID-19) had a significant impact on dermatology, as evidenced by the decrease in consultations and procedures, as well as the introduction of teledermatology (TD). During the pandemic, many dermatologists employed teledermatology.
Actinic keratosis cases have increased as a result of an increase in baldness, skin wrinkling, and sunburn patches. Compared to patients from other regions, those from New Zealand and Australia in particular, frequently displayed higher negative consequences of sun exposure since actinic keratosis is more common in nations that are closer to the equator. Australia has an actinic keratosis prevalence rate that is very close to half of its population due to its proximity to the equator.
The China market dominated the Asia Pacific Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $607.9 Million by 2028. The Japan market is estimated to grow a CAGR of 4.5% during (2022-2028). Additionally, The India market would display a CAGR of 5.8% during (2022-2028).
Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.
There are numerous actinic keratosis treatment methods nowadays. The most commonly employed methods include cryotherapy, excision, chemical peels, and photodynamic therapy. A chemical peel resembles a high-end face mask. During an office visit, the healthcare professional apply the peel. The treatment's ingredients safely remove any unwelcome skin growths from the epidermis. The treated region remains painful and red for the first few days.
Before beginning the excision procedure, the doctor numbs the area around the AK. The AKs are then removed surgically or by scraping, and the wound is stitched back up. The wound typically heals in two to three weeks. Photodynamic therapy may be suggested by the doctor if patients have several AKs or AKs that recur after treatment. In order to eliminate precancerous skin cells, this treatment employs lotions and specialized light therapy. While the treated skin heals, the patient will need to avoid the sun for a few days.
Additionally, the coronavirus disease pandemic of 2019 (COVID-19) had a significant impact on dermatology, as evidenced by the decrease in consultations and procedures, as well as the introduction of teledermatology (TD). During the pandemic, many dermatologists employed teledermatology.
Actinic keratosis cases have increased as a result of an increase in baldness, skin wrinkling, and sunburn patches. Compared to patients from other regions, those from New Zealand and Australia in particular, frequently displayed higher negative consequences of sun exposure since actinic keratosis is more common in nations that are closer to the equator. Australia has an actinic keratosis prevalence rate that is very close to half of its population due to its proximity to the equator.
The China market dominated the Asia Pacific Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $607.9 Million by 2028. The Japan market is estimated to grow a CAGR of 4.5% during (2022-2028). Additionally, The India market would display a CAGR of 5.8% during (2022-2028).
Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.
Scope of the Study
By Drug Class
- Nucleoside Metabolic Inhibitor
- NSAIDs
- Immune Response Modifiers
- Photoenhancers
- Others
By Therapy
- Surgery
- Topical
- Photodynamic Therapy
By End-use
- Hospitals
- Private Clinics
- Homecare
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Almirall, S.A
- LEO Pharma A/S
- Biofrontera AG
- Sun Pharmaceuticals Industries Ltd.
- 3M Company
- Bausch Health Companies, Inc.
- Novartis AG
- Viatris, Inc.
- Galderma S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Actinic Keratosis Treatment Market by Drug Class
Chapter 4. Asia Pacific Actinic Keratosis Treatment Market by Therapy
Chapter 5. Asia Pacific Actinic Keratosis Treatment Market by End-use
Chapter 6. Asia Pacific Actinic Keratosis Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Almirall, S.A
- LEO Pharma A/S
- Biofrontera AG
- Sun Pharmaceuticals Industries Ltd.
- 3M Company
- Bausch Health Companies, Inc.
- Novartis AG
- Viatris, Inc.
- Galderma S.A.
Methodology
LOADING...
